HHSO100201600030C↗
Emergent Product Development Gaithersburg Inc. received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $288.48M obligated so far for health r&d services; health care services; applied research. Its period of performance ended 2026-09-29.
Key facts · data as of Oct 25, 2026
- Recipient
- Emergent Product Development Gaithersburg Inc.
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $288.48M
- Potential value
- $1.46B
- Ends
- 2026-09-29
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award HHSO100201600030C, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_HHSO100201600030C_7505_-NONE-_-NONE-
Emergent Product Development Gaithersburg Inc.: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys · The follow-on: recompete brief
IGF::OT::IGF
Up for re-bid: ends 2026-09-29. Recompete brief → · Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response ↗
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in Biotechnology (NAICS 541711)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Cost plus fixed fee
- How it was bought
- Standalone contract
- Solicitation
- 16100SOL00015
- Where the work is
- Montgomery, MD · district MD-06
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
9 actions since 2023-03-30. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-18 | P00021 | Option exercised | $23.98M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2025-08-29 | P00020 | Option exercised | $30.00M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2025-04-04 | P00019 | Change order | $0 | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2024-12-12 | P00018 | Option exercised | $50.00M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2024-06-26 | P00017 | Option exercised | $30.00M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2023-11-21 | P00016 | Option exercised | $75.00M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2023-10-06 | P00015 | Change order | $0 | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2023-06-16 | P00014 | Option exercised | $75.00M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| 2023-03-30 | P00013 | Change order | $4.50M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗